Muna Therapeutics develops therapies aimed at slowing or halting neurodegenerative diseases, specifically targeting the underlying mechanisms of Alzheimer’s and Parkinson’s. The company utilizes advanced drug discovery techniques to create disease-modifying treatments that address the progressive nature of these conditions.
Funding
$75.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Neurodegenerative diseases like Alzheimer's and Parkinson's currently lack effective treatments that can halt or significantly slow disease progression. Existing therapies primarily address symptoms rather than targeting the underlying mechanisms driving neuronal damage and cognitive decline. This leaves a significant unmet need for disease-modifying interventions.
Solution
Muna Therapeutics is developing a portfolio of novel therapeutics designed to slow or stop the progression of neurodegenerative diseases, with a primary focus on Alzheimer's and Parkinson's. The company employs advanced drug discovery techniques to identify and develop treatments that target the fundamental mechanisms underlying these conditions. By addressing the root causes of neurodegeneration, Muna Therapeutics aims to create disease-modifying therapies that can improve long-term outcomes for patients. Their approach seeks to move beyond symptomatic relief and offer a more substantive impact on disease trajectory.
Target Audience
The primary target audience includes patients diagnosed with Alzheimer's disease, Parkinson's disease, and related neurodegenerative disorders, as well as their caregivers and healthcare providers.
Features
- Focus on identifying and validating novel drug targets relevant to neurodegenerative disease pathways.
- Utilization of advanced drug discovery platforms, including high-throughput screening and computational modeling.
- Development of small molecule and biologic therapeutics with potential for blood-brain barrier penetration.
- Preclinical studies to evaluate efficacy and safety of drug candidates in relevant disease models.